A better way to treat cancer, Brian Druker
Interviewee: Brian Druker. Brian Druker talks bout a better way to treat cancer.
Related Content
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
16109. Sense of urgency, Brian Druker
Brian Druker talks about sense of urgency.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15058. The first clinical success with Gleevec, Brian Druker
Brian Druker talks about Bud, the first patient restored to health by Gleevecâ¢.
1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
1010. Diagnosis, Targeted therapies
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.